<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Perin, Emerson</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Neutral Outcomes but Important Insights from FOCUS-CCTRN</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">22-22</style></pages><abstract><style  face="normal" font="default" size="100%">Cell therapy has emerged as an exciting and innovative approach for treating patients with advanced ischemic heart disease, including those with refractory angina and/or heart failure [Perin EC et al. JAMA 2012]. The FOCUS-CCTRN trial [NCT00824005] was designed to evaluate the safety and efficacy of bone marrow mononuclear cells in patients with chronic ischemic heart disease and left ventricular dysfunction with no other revascularization options.</style></abstract><number><style face="normal" font="default" size="100%">4</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>